Impact of Patent Expiration on Key Drugs Categories for 2012-2016 - A Survey Report
NEW YORK, Dec. 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Impact of Patent Expiration on Key Drugs Categories for 2012-2016 - A Survey Report
http://www.reportlinker.com/p01055031/Impact-of-Patent-Expiration-on-Key-Drugs-Categories-for-2012-2016----A-Survey-Report.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
TechNavio's analysts have conducted a survey on Impact of Patent Expiration on Key Drugs Categories for 2012-2016. The survey assessed the Impact of Patent Expiration on several key drugs categories such as Antipsychotic drugs, Antibiotics, ADHD drugs, Antacid drugs, Antiplatelet drugs, Asthma drugs, Diabetes drugs, Arthritis drugs, HIV drugs, Epilepsy drugs, and Cardiovascular drugs. The survey also covers the strategies adopted before patent expiration, strategies adopted to counter patent expirations, organizational impacts, and their sales impacts. Based on the overall factors, the impact of patent expiration on key drugs categories was studied for the period 2012-2016.
TechNavio's report, Impact of Patent Expiration on Key Drugs Categories for 2012-2016 - A Survey Report, has been prepared based on responses from over 200 participants across patented drug manufacturers, generic drug manufacturers, and a combination of both. The survey participants were selected from more than 15 top countries in the Global Pharmaceuticals market.
The vendors mentioned in the report are ABX GmbH, Ache Laboratorios SA, ACI Limited, Ajanta Pharma Ltd., Alphapharm Pty Ltd., AstraZeneca Europe, AstraZeneca India, Astrazeneca do Brasil LTDA, Baxter Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim, CCL Pharmaceuticals Pvt. Ltd., Cipla Ltd., Covidien India Healthcare Limited, Dr Reddy's Laboratories Ltd., Eurofarma Laboratories Ltd., Ferring Pharmaceuticals, Genus Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Healthcare Pharmaceuticals Ltd., Hospira Australia Pty Ltd., iNova Pharmaceuticals, LEO Pharma, Medley Pharmaceuticals Ltd., Merck Sharp & Dohme, MSD Pharmaceuticals Pvt. Ltd., Novartis International AG, Novartis de Colombia, Novartis farma Italy, Panacea Biotec Ltd., Pfizer Inc., PharmOut Pty Ltd., APP Pharmaceuticals, F. Hoffmann-La Roche Ltd., Sandoz GmbH, Sandoz India Pvt Ltd., Sanofi SA, Schwabe Pharmaceuticals, Torrent Pharma, Vifor Pharma Ltd., Wanbury Ltd, and Wockhardt Ltd.
Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of analyst time when you purchase this report. Details provided within the report.
TechNavio's research portfolio in the Healthcare series includes reports on the Pharmaceutical Market, Medical Devices Market, Diagnostic Market, Vaccine Market, Oncology Market, CRO Market, Orthopedic Market, Hearing Aids Market, Dental Care Market, Medical Imaging Market, Endoscopy Market, Dialysis Market, Telemedicine Market, Cancer Drug Market, Glucose Monitoring Market, Infusion Pumps Market, Defibrillators Market, Neuromodulation Market, Capnography Market.
Methodology
Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.
01. Introduction
02. Scope of the Study
Overview
Objective
Survey Respondents
Selection Methodology
Selection Criteria
03. Respondent Profile
Profile by Designations
Profile by Nature of Work
Profile by Country
04. Industry Background
Business Type of the Companies
Number of Years in the Pharmaceutical Business
Medicinal Segments of Organizations
List of Companies that Participated in the Survey
05. Strategies Adopted Before Patent Expirations
Timeframe for Action Plan
Taking Part in a Merger or Acquisition
Phasing Out the Product
Rebranding the Product
Increasing the Market Penetration
Developing New and Alternative Products
Entering the Biosimilars Market
Reducing the Sales Force
Consolidated List of Responses for Strategies Adopted by Pharmaceutical Companies
Consolidated List of Responses for Strategies Adopted by Patented Drug Manufacturers Companies
06. Impact of Patent Expirations on Sales of Drugs in Key Drugs Categories
Antipsychotic Drugs
Antibiotics
ADHD Drugs
Antacid Drugs
Antiplatelet Drugs
Asthma Drugs
Diabetes Drugs
Arthritis Drugs
HIV Drugs
Epilepsy Drugs
Cardiovascular Drugs
Impact of Patent Expirations on the Sales of Drugs in Key Drug Categories
07. Strategies Adopted by Organizations to Counter the Impact of Patent Expiration
Launching New Products
Altering the Product
Phasing Out the Product
Reducing the Price of the Product
Increasing Marketing Activities
Rebranding the Product
Forming Strategic Alliances
Increasing Market Penetration
Entering New Markets
Consolidation of Strategies Adopted by Organizations to Counter the Impact of Patent Expiration
08. Organizational Impacts of Patent Expiration
Impact on Product Pricing
Impact on Marketing Expenses
Impact on Product Sales
Impact on R&D Investments
Impact on New Product Launches
Impact on Brand Equity
Consolidation of Major Organizational Impacts of Patent Expiration
09. Impact of Patent Expirations on Sales of OTC and Prescription Drugs
Sales of OTC Drugs
Sales of Prescription Drugs
10. Scenario of Pharmaceuticals after Patent Expirations
Entry of New Suppliers
Changes in Ingredients and Composition of Drugs
Change in Brand Name
11. Conclusion
12. Other Reports in this Series
List of Exhibits:
Exhibit 1: Survey Respondents
Exhibit 2: Methodology for Conducting the Survey
Exhibit 3: Respondent Profile by Designations
Exhibit 4: Respondent Profile by Nature of Work
Exhibit 5: Respondents by Country
Exhibit 6: Business Type of the Pharmaceutical Companies
Exhibit 7: Number of Years in Pharmaceutical Business
Exhibit 8: Medicinal Segments of Organizations
Exhibit 9: Timeframe for Action Plan to Counter Drug Patent Expiration
Exhibit 10: Taking Part in a Merger or Acquisition
Exhibit 11: Phasing Out the Product
Exhibit 12: Rebranding the Product
Exhibit 13: Increasing the Market Penetration
Exhibit 14: Developing New and Alternate Products
Exhibit 15: Entering the Biosimilars Market
Exhibit 16: Reducing the Sales Force
Exhibit 17: Responses for Strategies Adopted by Pharmaceutical Companies
Exhibit 18: Responses for Strategies Adopted by Patented Drug Manufacturers
Exhibit 19: Impact of Patent Expirations on Sales of Antipsychotic Drugs
Exhibit 20: Impact of Patent Expirations on Sales of Antibiotic Drugs
Exhibit 21: Impact of Patent Expirations on Sales of ADHD Drugs
Exhibit 22: Impact of Patent Expirations on Sales of Antacid Drugs
Exhibit 23: Impact of Patent Expirations on Sales of Antiplatelet Drugs
Exhibit 24: Impact of Patent Expirations on Sales of Asthma Drugs
Exhibit 25: Impact of Patent Expirations on Sales of Diabetes Drugs
Exhibit 26: Impact of Patent Expirations on Sales of Arthritis Drugs
Exhibit 27: Impact of Patent Expirations on Sales of HIV Drugs
Exhibit 28: Impact of Patent Expirations on Sales of Epilepsy Drugs
Exhibit 29: Impact of Patent Expirations on Sales of Cardiovascular Drugs
Exhibit 30: Impact of Patent Expirations on the Sales of Drugs in Key Drug Categories
Exhibit 31: Launching New Products
Exhibit 32: Altering the Product
Exhibit 33: Phasing Out the Product
Exhibit 34: Reducing the Price of the Product
Exhibit 35: Increasing Marketing Activities
Exhibit 36: Rebranding the Product
Exhibit 37: Forming Strategic Alliances
Exhibit 38: Increasing Market Penetration
Exhibit 39: Entering New Markets
Exhibit 40: Consolidation of Strategies Adopted by Organizations to Counter the Impact of Patent Expiration
Exhibit 41: Impact on Product Pricing
Exhibit 42: Impact on Marketing Expenses
Exhibit 43: Impact on Product Sales
Exhibit 44: Impact on R&D Investments
Exhibit 45: Impact on New Product Launches
Exhibit 46: Impact on Brand Equity
Exhibit 47: Consolidation of Major Organizational Impacts of Patent Expiration
Exhibit 48: Sales of Over-the-Counter Drugs
Exhibit 49: Sales of Prescription Drugs
Exhibit 50: Entry of New Suppliers
Exhibit 51: Changes in Ingredients and Composition of Drugs
Exhibit 52: Change in Brand Name
To order this report:
Drug_and_Medication Industry: Impact of Patent Expiration on Key Drugs Categories for 2012-2016 - A Survey Report
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article